Tumor-specific cytolysis caused by an E1B55K-attenuated adenovirus in nasopharyngeal carcinoma is augmented by cisplatin

Anatomical Record

Volumn 296, Issue 12, 2013, Pages 1833-1841

  Liu, Ran Yi ^a   Peng, Ji Lin ^a,b   Li, Yong Qiang ^a   Huang, Bi Jun ^a   Lin, Huan Xin ^a   Zhou, Ling ^a   Luo, Hui Ling ^a   Huang, Wenlin ^a,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c Science Park   (China)

Author keywords

Chemotherapy; Cisplatin; dl1520; E1B55K attenuated adenovirus; Nasopharyngeal carcinoma

Indexed keywords

CISPLATIN; LONTUCIREV;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL DIVISION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; MUS MUSCULUS;

CHEMOTHERAPY; CISPLATIN; DL1520; E1B55K-ATTENUATED ADENOVIRUS; NASOPHARYNGEAL CARCINOMA;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; TUMOR CELLS, CULTURED; VACCINES, ATTENUATED; VIRAL VACCINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888068550     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22813     Document Type: Article

References (35)

1. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM. 2012. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 31:185-196.
2. Alemany R. 2007. Cancer selective adenoviruses. Mol Aspects Med 28:42-58.
3. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP. 2006. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47-56.
4. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
5. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. 2000. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 19:3439-3444.
6. Goodrum FD, Ornelles DA. 1997. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol 71:548-561.
7. Graham FL, Prevec L. 1991. Manipulation of adenovirus vectors. In: Murray EJ, editor. Methods in molecular biology: gene transfer and expression protocols. Clifton, NJ: Human Press. p 109-128.
8. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639-645.
9. Hobom U, Dobbelstein M. 2004. E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol 78:7685-7697.
10. Hoe SL, Lee ES, Khoo AS, Peh SC. 2009. p53 and nasopharyngeal carcinoma: a Malaysian study. Pathology 41:561-565.
11. Huang DC, Cory S, Strasser A. 1997. Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 14:405-414.
12. Jin ZJ. 2004. About the evaluation of drug combination. Acta Pharmacol Sin 25:146-147.
13. Levine AJ. 2009. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 384:285-293.
14. Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH, Zeng YX, Huang W. 2006. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer 118:2064-2071.
15. Li M, Chen J, Wang H. 1998. p53 mutation in nasopharyngeal carcinoma. Chin J Cancer 17:246-248.
16. Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK, Chen J, Petillo D, Teh BT, Qian CN, Zhang JT. 2011. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene 30:4814-4823.
17. Liu RY, Luo HL, Feng HL, Peng JL, Cai TY, Huang WL, Zeng YX. 2002. A method to detect gene transfection efficacy by flow cytometry. Chin J Cancer 21:267-271.
18. Lung ML, Hu Y, Cheng Y, Li MF, Tang CM, O SK Iggo RD. 1998. p53 inactivating mutations in Chinese nasopharyngeal carcinomas. Cancer Lett 133:89-94.
19. McCormick F. 2000. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin Cancer Biol 10:453-459.
20. McNeish IA, Bell SJ, Lemoine NR. 2004. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther 11:497-503.
21. Murono S, Yoshizaki T, Park CS, Furukawa M. 1999. Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology 34:432-438.
22. O'Shea CC. 2005. Viruses-seeking and destroying the tumor program. Oncogene 24:7640-7655.
23. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. 2004. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6:611-623.
24. O'Shea CC, Soria C, Bagus B, McCormick F. 2005. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8:61-74.
25. Pan XB, Zhu XD. 2012. Role of chemotherapy in stage IIb nasopharyngeal carcinoma. Chin J Cancer 31:573-578.
26. Putzer BM, Stiewe T, Parssanedjad K, Rega S, Esche H. 2000. E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ 7:177-188.
27. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM. 2000. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 6:1128-1133.
28. Rivlin N, Brosh R, Oren M, Rotter V. 2011. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2:466-474.
29. Sanchez-Prieto R, Quintanilla M, Cano A, Leonart ML, Martin P, Anaya A, Ramon y Cajal S. 1996. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 13:1083-1092.
30. Spruck CHIII, Tsai YC Huang DP Yang AS Rideout WMIII Gonzalez-Zulueta M Choi P Lo KW Yu MC Jones PA. 1992. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 52:4787-4790.
31. Steegenga WT, Riteco N, Bos JL. 1999. Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and DeltaE1B adenovirus replication in human cells. Oncogene 18:5032-5043.
32. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J. 2003. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197:93-98.
33. Xue G, Liu RY, Li Y, Cheng Y, Liang ZH, Wu JX, Zeng MS, Tian FZ, Huang W. 2007. Dendritic cells modified with 6Ckine/IFNgamma fusion gene induce specific cytotoxic T lymphocytes in vitro. Cancer Immunol Immunother 56:1831-1843.
34. Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC. 2010. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Oncogene 29:5619-5629.
35. Yang HJ, Cho YJ, Kim HS, Chang MS, Sung MW, Kim WH. 2001. Association of p53 and BCL-2 expression with Epstein-Barr virus infection in the cancers of head and neck. Head Neck 23:629-636.